Extracellular matrix changes in colorectal carcinoma and correlation with lymph node metastasis

The process of proliferation and invasion of tumor cells depends on changes in the extracellular matrix (ECM) through the activation of enzymes and alterations in the profile of ECM components. We aimed to investigate the mRNA and protein expression of ECM components such as heparanase (HPSE), heparanase-2 (HPSE2), matrix metalloproteinase-9 (MMP-9), and syndecan-1 (SYND1) in neoplastic and non-neoplastic tissues of patients with colorectal carcinoma (CRC). It is a cross-sectional study in which twenty-four adult patients that had CRC were submitted to resection surgery. We analyzed the expression of HPSE, HPSE2, MMP-9, and SYND1 by quantitative RT-PCR and immunohistochemistry. Differing from most of the studies that compare the mRNA expression between tumor samples and non-neoplastic tissues, we decided to investigate whether variations exist in the expression of the ECM components between the affected tissue and nontumoral tissue collected from the same patient with CRC. We removed both tissue samples immediately after the surgical resection of CRC. The data showed higher mRNA and protein expression of HPSE2 (P = 0.0058), MMP-9 (P = 0.0268), and SYND1 (P = 0.0002) in tumor samples compared to the non-neoplastic tissues, while there was only an increase in the level of HPSE protein in tumor tissues. A greater expression of HPSE2 was observed in patients with lymph node metastasis (P = 0.048), suggesting that such protein can be a marker of lymph node metastasis in CRC.

[1]  G. Z. Justo,et al.  Crosstalk between tumor cells and lymphocytes modulates heparanase expression , 2019, Journal of Translational Medicine.

[2]  M. Ivarsson,et al.  Stability of matrix metalloproteinase-9 as biological marker in colorectal cancer , 2018, Medical Oncology.

[3]  G. Pentheroudakis,et al.  Current and future biomarkers in colorectal cancer , 2017, Annals of gastroenterology.

[4]  Preeti Singh,et al.  The Heparanase Inhibitor PG545 Attenuates Colon Cancer Initiation and Growth, Associating with Increased p21 Expression1 , 2017, Neoplasia.

[5]  R. Sanderson,et al.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy , 2017, The FEBS journal.

[6]  Preeti Singh,et al.  Heparanase: From basic research to therapeutic applications in cancer and inflammation. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  J. S. Andrade-Filho,et al.  Matrix metalloproteinase 9 -1562C/T polymorphism increased protein levels in patients with colorectal cancer in a sample from southeastern Brazil. , 2016, Genetics and molecular research : GMR.

[8]  T. R. Theodoro,et al.  Immunohistochemical Expression of Heparanase Isoforms and Syndecan-1 Proteins in Colorectal Adenomas , 2016, European journal of histochemistry : EJH.

[9]  Li-Sheng Chen,et al.  Prognostic and clinical significance of syndecan-1 in colorectal cancer: a meta-analysis , 2015, BMC Gastroenterology.

[10]  A. Shteingauz,et al.  Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy. , 2015, Cancer research.

[11]  J. Cubiella,et al.  Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening , 2015, Scientific Reports.

[12]  C. O'Sullivan,et al.  Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer , 2015, PloS one.

[13]  Shaoheng Zhang,et al.  High glucose-induced intestinal epithelial barrier damage is aggravated by syndecan-1 destruction and heparanase overexpression , 2015, Journal of cellular and molecular medicine.

[14]  T. R. Theodoro,et al.  Immunohistochemical Expression of Heparanases 1 and 2 in Benign Tissue and in Invasive Neoplasia of the Endometrium: A Case-Control Study , 2015, International Journal of Gynecologic Cancer.

[15]  Y. Ba,et al.  Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer , 2014, British Journal of Cancer.

[16]  A. Shteingauz,et al.  Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and α-actinin , 2014, Cellular and Molecular Life Sciences.

[17]  G. Gambaro,et al.  Heparanase as a target in cancer therapy. , 2014, Current cancer drug targets.

[18]  J. Raufman,et al.  The Role of Matrix Metalloproteinases in Colorectal Cancer , 2014, Cancers.

[19]  A. Purushothaman,et al.  The heparanase/syndecan‐1 axis in cancer: mechanisms and therapies , 2013, The FEBS journal.

[20]  A. Purushothaman,et al.  Heparanase Regulates Secretion, Composition, and Function of Tumor Cell-derived Exosomes*♦ , 2013, The Journal of Biological Chemistry.

[21]  Z. Tulassay,et al.  The Behavior of Matrix Metalloproteinases and Their Inhibitors in Colorectal Cancer , 2012, International journal of molecular sciences.

[22]  E. Ioachim,et al.  Association of syndecan-1 with angiogenesis-related markers, extracellular matrix components, and clinicopathological features in colorectal carcinoma. , 2012, Anticancer research.

[23]  T. R. Theodoro,et al.  The Immunoexpression of Heparanase 2 in Normal Epithelium, Intraepithelial, and Invasive Squamous Neoplasia of the Cervix , 2012, Journal of lower genital tract disease.

[24]  Cornelis F. M. Sier,et al.  MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients , 2012, British Journal of Cancer.

[25]  T. Peretz,et al.  Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. , 2011, The Journal of clinical investigation.

[26]  T. R. Theodoro,et al.  Heparanase isoform expression and extracellular matrix remodeling in intervertebral disc degenerative disease , 2011, Clinics.

[27]  A. Shteingauz,et al.  Heparanase 2 Interacts with Heparan Sulfate with High Affinity and Inhibits Heparanase Activity* , 2010, The Journal of Biological Chemistry.

[28]  H. Nader,et al.  Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma , 2008, European journal of gastroenterology & hepatology.

[29]  Josephine C. Adams,et al.  Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: An immunohistochemical study of clinically annotated tumors , 2008, BMC Cancer.

[30]  L. Martins,et al.  Heparanase expression in circulating lymphocytes of breast cancer patients depends on the presence of the primary tumor and/or systemic metastasis. , 2007, Neoplasia.

[31]  J. Isola,et al.  Epithelial Syndecan-1 Expression Is Associated with Stage and Grade in Colorectal Cancer , 2005, Oncology.

[32]  T. Peretz,et al.  Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. , 2004, Journal of the National Cancer Institute.

[33]  佐藤 知洋.  Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis and prognosis , 2004 .

[34]  T. Peretz,et al.  Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. , 2000, The American journal of pathology.

[35]  J. Platt,et al.  Heparanase, a potential regulator of cell-matrix interactions. , 2000, Trends in biochemical sciences.